Kalaris Therapeutics Inc (KLRS) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.84
↓-49% vs avg
5yr avg: 1.63
30Y Low1.6·High1.6
ROE
↑
-45.2%
↓+38% vs avg
5yr avg: -73.2%
30Y Low-172%·High-11%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KLRS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kalaris Therapeutics Inc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $81M | $129M | — | — | — | — | — | — | — |
| Enterprise Value | $-15623326 | $32M | — | — | — | — | — | — | — |
| P/E Ratio → | -1.52 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.84 | 1.63 | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KLRS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
KLRS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -45.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | -16182.4% | -316.8% |
| Net Profit Margin | — | — | — | — | — | — | — | -14447.9% | -214.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.2% | -45.2% | -172.1% | — | -15.9% | -59.5% | -29.4% | -33.3% | -11.3% |
| ROA | -36.2% | -36.2% | -96.4% | -406.5% | -10.7% | -52.3% | -27.4% | -28.9% | -9.6% |
| ROIC | — | — | — | — | -89.0% | -87.0% | -34.3% | -58.1% | — |
| ROCE | -41.0% | -41.0% | -98.1% | — | -11.3% | -55.9% | -29.2% | -35.2% | -16.7% |
KLRS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $98M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | — | — | 0.13 | 0.02 | 0.10 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.23 | -1.04 | — | — | -0.76 | -0.32 | -0.41 | -1.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | -12.85 |
| Interest Coverage | -31.98 | -31.98 | — | -20.40 | -64.89 | — | — | — | — |
Net cash position: cash ($98M) exceeds total debt ($1M)
KLRS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kalaris Therapeutics Inc's current ratio of 12.23x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.85x to 12.23x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.23 | 12.23 | 22.63 | 0.85 | 0.69 | 6.69 | 29.39 | 13.98 | 6.77 |
| Quick Ratio | 12.23 | 12.23 | 22.63 | 0.85 | 0.69 | 6.69 | 29.39 | 13.98 | 6.77 |
| Cash Ratio | 12.15 | 12.15 | 22.58 | 0.80 | 0.54 | 6.55 | 28.98 | 13.85 | 6.68 |
| Asset Turnover | — | — | — | — | — | — | — | 0.00 | 0.04 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 1238.79 | 97.12 |
KLRS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kalaris Therapeutics Inc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $15M | $5M | $5M | $3M | $3M | $1M | $3M | $3M |
Peer Comparison
Compare KLRS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KLRSYou | $81M | -1.5 | — | — | — | — | -45.2% | — | — |
 REPL | $733M | -2.9 | — | — | — | — | -62.6% | -51.9% | — |
 ADMA | $2B | 13.7 | 9.5 | 68.4 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 TGTX | $8B | 17.9 | 62.8 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -187.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 RCUS | $2B | -7.2 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 FATE | $240M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 AGEN | $137M | -970.6 | — | — | 29.6% | -18.0% | — | — | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
What if you invested $1,000 in KLRS 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in KLRS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KLRS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKLRS vs REPL — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Replimune Group, Inc..
Compare NowKLRS — Frequently Asked Questions
Quick answers to the most common questions about buying KLRS stock.
What is Kalaris Therapeutics Inc's P/E ratio?
Kalaris Therapeutics Inc's current P/E ratio is -1.5x. This places it at the 50th percentile of its historical range.
What is Kalaris Therapeutics Inc's ROE?
Kalaris Therapeutics Inc's return on equity (ROE) is -45.2%. The historical average is -52.4%.
Is KLRS stock overvalued?
Based on historical data, Kalaris Therapeutics Inc is trading at a P/E of -1.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.